GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (LSE:GSK) » Definitions » Cash Flow from Financing

GSK (LSE:GSK) Cash Flow from Financing : £-2,808 Mil (TTM As of Mar. 2025)


View and export this data going back to 1972. Start your Free Trial

What is GSK Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2025, GSK paid £235 Mil more to buy back shares than it received from issuing new shares. It received £1,918 Mil from issuing more debt. It paid £0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent £612 Mil paying cash dividends to shareholders. It spent £156 Mil on other financial activities. In all, GSK earned £915 Mil on financial activities for the three months ended in Mar. 2025.


GSK Cash Flow from Financing Historical Data

The historical data trend for GSK's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cash Flow from Financing Chart

GSK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10,132.00 -7,589.00 823.00 -5,641.00 -4,726.00

GSK Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,060.00 -1,584.00 -1,240.00 -842.00 858.00

GSK Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

GSK's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

GSK's Cash from Financing for the quarter that ended in Mar. 2025 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was £-2,808 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GSK  (LSE:GSK) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

GSK's issuance of stock for the three months ended in Mar. 2025 was £12 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

GSK's repurchase of stock for the three months ended in Mar. 2025 was £-247 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

GSK's net issuance of debt for the three months ended in Mar. 2025 was £1,918 Mil. GSK received £1,918 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

GSK's net issuance of preferred for the three months ended in Mar. 2025 was £0 Mil. GSK paid £0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

GSK's cash flow for dividends for the three months ended in Mar. 2025 was £-612 Mil. GSK spent £612 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

GSK's other financing for the three months ended in Mar. 2025 was £-156 Mil. GSK spent £156 Mil on other financial activities.


GSK Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of GSK's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.